C-Rad AB (publ) (CRAD_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the C-RAD QT 2025 report presentation. For the first part of the presentation, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing hash 5 on their telephone keypad. Now I will hand the conference over to CEO Cecilia DeLeu and CFO Linda Frolian. Please go ahead. Welcome to our Q2 presentation and thank you for joining us today in the middle of the Swedish summer. We have concluded a busy quarter with high activity in all markets with an increased order intake and winning deals despite market uncertainty. And as many of you know, the foundation for our offering is the demand and need for safer cancer treatments with a focus on the patient's quality of life. And it's also about increasing efficiency in the customer's clinics. And we are on a journey. We are building an even stronger CWED, working hard on our financial strengths so that we can access both established and untapped markets globally with our world-leading products and services. So now let's take a look at the Q2 performance and the key takeaways. Q2 was indeed a busy quarter and we are taking steps towards our financial targets. And I am pleased that the hard work done by the team, driving marketing activities, participating in trade shows, organizing reference site visits, which is common in the final phase of the customer buying process, and all this hard work is paying off. We took a number of larger deals in both US and EMEA in the second quarter. Our order intake grew 11% in constant currencies. The main contribution came from EMEA and Americas. And we ended the quarter with a strong order backlog of 735 million SEC. And when looking at the backlog, approximately half of the order backlog consists of products a...